Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records reported in 2013

39 records with a recorded report or completion year of 2013.

Showing 0 records on this page

Records

39 documents · page 1 of 2

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
DURATION-6ExenatidePhase 3ReportedRandomised, open-label, active-controlled9112013High
DURATION-6-ADHERENCEprogramme recordExenatidePhase 3ReportedObservational2013Very low
DURATION-6-BIOMARKERprogramme recordExenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
DURATION-6-ELDERLYprogramme recordExenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
DURATION-6-OLEprogramme recordExenatidePhase 3ReportedSingle-arm open-label2013Very low
DURATION-6-REGIONAL-JPprogramme recordExenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-DUO-1LixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled4462013High
GETGOAL-DUO-1-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2013Very low
GETGOAL-DUO-1-ELDERLYprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-DUO-1-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-LLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled4952013High
GETGOAL-L-BODY-COMPprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-L-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2013Very low
GETGOAL-L-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-L-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-L-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-MLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled6802013High
GETGOAL-M-ADHERENCEprogramme recordLixisenatidePhase 3ReportedObservational2013Very low
GETGOAL-M-BIOMARKERprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-M-ELDERLYprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-M-OLEprogramme recordLixisenatidePhase 3ReportedSingle-arm open-label2013Very low
GETGOAL-M-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low

page 1 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.